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Abstract
Background: In the search for fast, simple and better ways for diagnosis of tuberculosis (TB), there is need to
discover and evaluate new biomarkers that are found in samples other than sputum to determine their
effectiveness. This study examined the utility of saliva vis-a-vis serum by evaluating levels of biomarkers found in
saliva and serum from TB suspects.
Methods: Study enrolled tuberculosis suspects. Sputum MGIT was used as the gold standard for active TB.
Quantiferon gold-In tube assay was done to identify exposure to Mycobacterium tuberculosis (M.tb). Multiplex assay
was run for 10 markers using a 10 plex customized kit from Bio-Rad Laboratories.
Results: There was a significant difference between saliva and serum marker levels. Saliva had significantly higher
levels of GM-CSF and VEGF. Serum had higher levels of MIP-1a, b, TNF-a, G-CSF and IFN-g. Serum levels of IL-6,
VEGF and TNF-a were significantly different between participants with active TB disease and those with other
respiratory diseases.
Conclusion: Salivary TB biomarkers are worth the search to evaluate their ability to differentiate between TB
disease states for generation of a non invasive point of care test for TB diagnosis.
Keywords: Biomarkers, Quantiferon, Saliva
Background
Globally, tuberculosis (TB) ranks alongside HIV as the
leading cause of mortality and morbidity [1]. The
diagnosis of the disease remains a major problem, due to
several shortcomings in the currently available diagnos-
tic tests. Smear microscopy, the most widely available
TB diagnostic test has poor sensitivity [2]. Sputum
culture, the gold standard has a long turnaround time
(up to 42 days) [3], whereas the recently developed
GeneXpert MTB/RIF test (Cepheid Inc., Sunnyvale,
USA), although rapid, is expensive, amongst other limi-
tations which hamper its use in resource-poor countries
[4]. All these tests also depend on the quality of sputum
provided by the patient, to yield reliable results. This is
highly problematic in children who cannot cough, and
in individuals with extra pulmonary TB.
Current research has given birth to immunodiagnostic
tests including the interferon gamma release assays
(IGRA) such as the Quantiferon TB Gold and the T-
SPOT assays. These tests require a blood draw to evaluate
the body’s T cell response towards Mycobacterium tuber-
culosis (Mtb), as a means to diagnose infection with Mtb
infection. These assays are based on the principle that in-
dividuals who have previously been exposed to Mtb
habour pre-activated T cells in circulation, which rapidly
respond with the secretion of IFN-γ after re-challenge in
vitro, with Mtb specific antigens. IGRAs have been shown
to be useful in the diagnosis of Mtb infection especially in
comparison with the tuberculin skin test. However, they
are not able to discriminate with latent Mtb infection and
active TB disease. This therefore means that the assays are
not useful in settings with high prevalence of latent TB.
Another limitation of these assays is the fact that they are
overnight assays, requiring a second visit to the hospital.
Assays based on ex-vivo samples such as serum, saliva or
whole blood, may be more beneficial as they may lead
to a more rapid diagnosis, and tests based on such as-
says may be easily converted to point-of-care tests.* Correspondence: annamuganga@gmail.com1Joint Clinical Research Centre, Kampala, Uganda
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When compared to serum, saliva has advantages
which include; low protein content, easy non invasive
collection and ease of storage [5–7]. Saliva has previ-
ously been used for molecular DNA testing in diagnosis
of systemic diseases like hepatitis [8] HIV, renal diseases,
cardiovascular diseases, autoimmune diseases, cancer,
diabetes and other infectious diseases [9]. Recently, more
studies have ventured into the search for biomarkers of
TB in saliva [10, 11]. Compared to blood, saliva has ad-
vantages as a specimen for TB diagnosis which include
none-invasiveness, no need for skilled personnel for col-
lection, none clotting ability and ease to handle [12]. A
study by Phalane et al. [13], compared serum with saliva
and it was shown that some host inflammatory bio-
markers are expressed in much higher concentrations in
saliva than are in blood. Further studies also showed that
some of the host markers detected in saliva showed po-
tential as diagnostic biomarkers for TB disease [10, 11].
However all these previous TB studies have only been
done on samples collected from a single study site. It is
known from previous immunological studies [14] that
immune responses tend to differ in patients recruited
from different African countries, thereby highlighting
the need for potential immunological based biomarkers
to be investigated in different geographical regions. In
the present study, we evaluated the expression of host
biomarkers in serum in comparison to saliva, and fur-
ther investigated whether any of these biomarkers had
potential in differentiating active TB disease from latent
or no TB infection, in individuals with presumed TB
disease, recruited from Mulago hospital study site in
Uganda. Replication of the findings from previous South
African studies [10, 11, 13] in the present study would
make the case for further investigation of the candidate
markers identified so far and other recently identified
markers in future larger studies and ultimately, the
possible development of fiend-friendly TB diagnostic
tests based on such salivary signatures. Furthermore, as
saliva is a mucosal/airway linked sample and is relatively
closer to the site of TB disease than peripheral blood,
saliva may be a more informative sample for biomarker
discovery purposes.
Methods
Study participants
Participants enrolled in this study were part of a bigger
African European Tuberculosis consortium (AETBC)
study that started in November 2010 and ended in
December 2012. This study enrolled adults with signs
and symptoms suggestive of TB disease (TB suspects),
prior to the establishment of a clinical diagnosis. Ugandan
study participants were recruited from within 25 km of
Mulago Hospital in Kampala. All study participants had
had cough for at least 2 weeks, in addition to any other
TB symptoms including fever, night sweats, uninten-
tional weight loss, chest pain, haemoptysis and contact
with an active TB case. These individuals also had no
history of TB treatment in the preceding 3 months.
Those who gave informed consent to participate in the
study were enrolled, samples collected and stored at
-80 °C. Of all the PTB suspects enrolled in the bigger
study, only 78 participants were selected. Serum and
saliva samples from these 78 PTB suspects were used
for this study. The study received ethical approval from
the Uganda National Council of Science and Technology
(UNCST), Makerere University College of Health Sciences
(MU-CHS) as well as the Joint Clinical Research Centre
(JCRC) institutional review boards.
All participants had chest x-ray, smear and culture
done for diagnosis of active pulmonary TB (PTB).
Sputum samples from all study participants were
cultured using the MGIT method (BD Biosciences) and
positive cultures were speciated to confirm Mtb
complex, regardless of the smear result.
Classification of study participants and reference standard
Using a combination of clinical, radiological, and labora-
tory findings, participants were classified as definite PTB
cases, probable TB cases, participants with other respira-
tory diseases (ORD). A positive culture result was used
to classify study participants as active PTB disease and a
negative culture accompanied by clinical features, radio-
logical findings was used to classify those with other
respiratory diseases (ORD) as described in the recent
paper by Chegou et al. [15]. Briefly, ORD cases had a
range of other diagnoses, including upper and lower
respiratory tract infections (viral and bacterial infections,
although attempts to identify organisms by bacterial or
viral cultures were not made), and acute exacerbations
of chronic obstructive pulmonary disease or asthma. In
assessing the accuracy of host biosignatures in the diag-
nosis of TB disease, all the definite and probable TB
cases were classified as active PTB, and then compared
to the ORD cases. In addition, those with negative cul-
ture (ORD) were re classified using the Quantiferon
Gold In Tube assay. The latent TB infection group had
positive quantiferon results while the No TB infection
group had a negative quantiferon result.
Sample collection and processing
Blood for serum separation was drawn into 8 ml serum
separation tubes (BD Biosciences) and transported to
the laboratory at ambient temperature. This was centri-
fuged at 2000×g for 10 min at room temperature. Serum
was then harvested, aliquoted and stored at -80 °C until
use. Saliva was drawn in salivette tubes (Sarsedt,
Germany) according to manufacturer’s instruction and
Namuganga et al. BMC Infectious Diseases  (2017) 17:600 Page 2 of 11
transported to the lab on ice. These were centrifuged at
1000×g for 2 min, aliquoted into labeled tubes and
stored at -80 °C until use.
Sputum samples were collected from all participants and
cultured using MGIT method (BD Biosciences). All sam-
ples that demonstrated growth of microorganisms were ex-
amined for acid-fast bacilli using the the Ziehl–Neelsen
method followed by either Capilia TB testing (TAUNS,
Numazu, Japan) or standard molecular methods, to
confirm the isolation of organisms of the M.tb complex.
Quantiferon Gold In Tube assay was used to identify
exposure to Mycobacterium tuberculosis.
Immunological assays
The Quantiferon Gold In Tube assay (QFT) was per-
formed on all study participants in order to diagnose
Mtb infection especially in the patients with ORD and
QFT results were not used for patient management or
for classification of study participants as TB or ORD. At
enrolment, all subjects had 3 ml of blood drawn for
QFT. IFN- γ levels in QFT supernatants were measured
using the QFT ELISA. As instructed by the manufac-
turer (Cellestis, Australia; now Qiagen, Germany), tests
were regarded as positive for TB infection if the differ-
ence between the TB antigen stimulated and unstimu-
lated (Nil) supernatant was greater than or equal to
0.35 IU/ml but greater than or equal to 25% of the Nil
value. The tests were regarded as negative if that
difference was <0.35 IU/ml and less than 25% of the Nil
value, provided that the value of mitogen stimulated
supernatant was ≥0.5 IU/ ml after subtraction of the
unstimulated value as per the manufacturer’s manual
[16]. The QFT analysis software, version 2.50 was used
for analysis.
Luminex immunoassay
The levels of 10 host markers were evaluated in serum and
saliva samples for all study participants using a 10 plex cus-
tomized kit from Bio-rad Laboratories (Hercules, CA,
USA) on the Bio-Plex platform (Bio Rad). These included
interferon gamma (IFN-γ), interleukin (IL) -2, 5, 6, gran-
ulocyte colony stimulating factor (G- CSF), granulocyte
monocyte colony stimulating factor (GM-CSF), macro-
phage inflammatory protein (MIP)-1α and β, vascular
endothelial growth factor (VEGF) and tumor necrosis fac-
tor alpha (TNF-α). As recommended by the manufacturer,
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Fig. 1 Median levels in pg/ml and interquartile ranges for all host markers in all study participants in both serum and saliva samples
Table 1 Participant characteristics
Variable All PTB No TB
LTBI Uninfected
No. of participants 78 39 21 18
Female 41(53%) 17(22%) 11 (14%) 13 (17%)
HIV positive % 13 (17%) 5 (6%) 2 (3%) 6 (8%)
QFT positive 57 (73%) 36 (46%) 21 (27%) 0
Abnormal X-ray 42 (54%) 34 (44%) 7 (9%) 1 (1%)
Table 1: The distribution of study participants according to their sputum MGIT
culture, Quantiferon and X-ray results is shown. All the TB patients were MGIT
positive. No TB cases (all MGIT negative) were further classified as LTBI or
uninfected individuals based on Quantiferon In Tube results. LTBI latent TB
infection, PTB active pulmonary TB disease
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the serum and saliva samples were diluted 1:4. Samples
from one study participant were tested on the same plate.
The Bio Plex Manager software, version 6.1 was used for
bead acquisition and analysis of median fluorescent
intensity.
Statistical analysis
Data were analyzed using GraphPad Prism, version 6.01
(GraphPad Soſtware, California, USA) and the statistica
software (StatSoft, USA). Differences in analyte levels
between the TB patients and participants without TB
disease or between the marker levels detected in saliva
and serum levels were evaluated by the Mann-Whitney
U test for nonparametric data analysis. The diagnostic
accuracy of the markers was investigated by receiver
operator characteristics (ROC) curve analysis. Optimal cut-
off values, sensitivity and specificity were selected based on
the highest likelihood ratio. The General discriminant
analysis technique (GDA) was used to evaluate the accur-
acy of combinations between different biomarkers for the
diagnosis of TB disease https://documents.software.dell.-
com/statistics/textbook/general-discriminant-analysis. This
employed the training and test set approach whereby study
participants were randomly split into a 70% training and
30% test set by the statistical software used in analysis
(Statistica) https://documents.software.dell.com/statistics/
textbook/general-discriminant-analysis. Differences between
groups were considered significant if p values were <0.05.
Results
Study participants
Of the 78 participants, 39 (50%) had confirmed PTB by
MGIT, 41 (53%) were females and 13 (16%) were HIV
positive. Of all participants, 57 (73%) had a positive QFT
as per the manufacturer’s recommended cut-off
(≥0.35 IU/mL). The mean age of all participants was
32 ± 14 years. Eight of the 39 participants in the ORD
group had abnormal chest X-rays which were consistent
with active TB (Table 1). A comparison was done to
evaluate if there was a difference in the markers pro-
duced by those participants who had No TB but had
abnormal x-ray (n = 8) and normal x-ray and without
TB (n = 31). The 8 participants with abnormal x-ray
were believed to have other chest infections. There
were no significant differences in the concentrations
of the host markers between these individuals and
other participants without TB disease and with
normal chest x rays.
Expression of host markers in serum and saliva samples
from all study participants
When the concentrations of host markers detected in
serum were compared to the levels detected in saliva in all
Table 3 Median levels of markers were significantly different
between saliva and serum for all active pulmonary TB participants
Marker Median (pg/ml) Saliva Median (pg/ml) serum p-value
IL-5 3.7 (2.7–4.7) 1.6 (0.6–2.7) <0.0001
IL-6 5.1 (2.4–9.5) 33.1 (12.9–60.3) <0.0001
G-CSF 0.0 (0.0–40.5) 76.1 (53.2–123.0) <0.0001
GM-CSF 257.9 (77.9–428.9) 0.0 (0.0–0.0) <0.0001
MIP-1a 1.9 (1.1–2.6) 6.41 (4.2–35.6) <0.0001
MIP-1b 0.0 (0.0–0.0) 178.1 (98.7–245.8) <0.0001
VEGF 1486 (104–1960) 224.6 (93.2–654.9) <0.0001
TNF-a 0.0 (0.0–8.5) 19.6 (7.4–26.6) <0.0001
IFNg 0.0 (0.0–15.6) 43.3 (0.94–74.3) 0.0003
Table 3: Shown are the marker levels that are significantly different (median
levels and inter quartile ranges (in parenthesis) in serum compared to saliva in
only active pulmonary TB participants with Area Under the ROC curve ranging
between 0.73–0.97
Table 4 Median levels of markers were significantly different
between saliva and serum for all participants
Marker Median (pg/ml) Saliva Median (pg/ml) serum p-value
IL-5 3.6 (2.7–4.7) 1.6 (0.6–2.1) <0.0001
IL-6 4.8 (2.1–5.4) 6.9 (5.6–9.9) <0.0001
G-CSF 0.0 (0.0–53.2) 72.5 (49.1–97.1) <0.0001
GM-CSF 282.2 (36.3–405.5) 0.0 (0.0–0.0) <0.0001
MIP-1a 1.9 (1.3–2.3) 7.39 (3.9–35.8) <0.0001
MIP-1b 0.0 (0.0–0.0) 201.9 (127.5–297.3) <0.0001
VEGF 1368 (550.5–2020) 57.1 (0–208.6) <0.0001
TNF-a 0.0 (0.0–4.3) 12.7 (8.5–19.1) <0.0001
IFNg 0.0 (0.0–7.7) 15.3 (10.4–52.9) 0.0003
Table 4: Shown are the marker levels that are significantly different (median
levels and ranges (in parenthesis) in serum compared to saliva in only
participants with other respiratory diseases with Area Under the ROC curve
ranging between 0.74–1
Table 2 Median levels of host markers were significantly
different between saliva and serum samples from all
participants, regardless of TB disease status
Marker Median (pg/ml) Saliva Median (pg/ml) serum p-value
IL-2 0.0 (0.0–46.2) 0.0 (0.0–121.0) 0.03
IL-5 1.6 (0.0–25.0) 3.6 (0.6–27.5) <0.0001
IL-6 4.9 (2.4–7.8) 10.17 (6.5–36.3) <0.0001
G-CSF 0.0 (0.0–50.1) 72.5 (52.2–103.7) <0.0001
GM-CSF 261.2 (40.4–409.1) 0.0 (0.0–0.0) <0.0001
MIP-1a 1.9 (1.1–2.5) 6.7 (4.2–35.6) <0.0001
MIP-1b 0.0 (0.0–0.0) 187.1 (114.4–260.4) <0.0001
VEGF 1467.2 (678.4–1975) 154 (0.0–322.2) <0.0001
TNF-a 0.0 (0.0–4.8) 14.8 (8.2–22.5) <0.0001
IFNg 0.0 (0.0–13.1 44.3 (8.1–60.6) 0.0003
Table 2: Shown are the median marker levels (inter quartile ranges in parenthesis)
for markers that were significantly different in serum compared to saliva in all
participants, regardless of TB disease status
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study participants, significant differences were ob-
served for all host markers, with p values ranging be-
tween <0.0001 and 0.03. Overall, the concentrations
of IL-2 and IL-5 in all participants were low
compared to other markers in both serum and saliva
samples regardless of the participants’ TB status.
However, the levels of IL-2 and IL-5 markers were
comparably higher in serum. The concentrations of
GM-CSF and VEGF were significantly higher in saliva
in comparison to serum, whereas the concentrations
of the other eight markers (IL-2, 5, 6, G-CSF, IFN-γ,
MIP-1α, MIP-1β, TNF-α) were significantly higher in
serum (Fig. 1, Table 2).
When the concentrations of the host markers detected
in saliva were compared to the concentrations obtained
in serum, but only in the TB patients, significant differ-
ences were observed for all markers (Table 3).
When the values obtained in the two sample types
were compared, but only in the no TB patients,
significant differences were observed for all markers with
AUCs greater than 0.73 (Table 4) with a p-value ranging
between <0.0001 and 0.0003 (Fig. 2).
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Fig. 2 Median and inter-quartile ranges (pg/ml) of all 10 markers showing the differences between the active TB group (PTB) and the No PTB
group (those with other respiratory diseases; ORD) in serum and saliva of all the study participants
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Abilities of host markers detected in serum and saliva in
the diagnosis of TB disease
When the concentrations of host markers detected in
serum samples were compared between the TB patients
and individuals with ORD with the Mann Whitney U
test, the concentrations of IL-6 and VEGF were signifi-
cantly different between the two groups. The concentra-
tions of IL-6 were significantly higher in active PTB
group (p = <0.0001) whereas the concentrations of
VEGF were significantly higher in ORD group
(p = 0.001). When the accuracy of the serum biomarkers
were assessed by ROC curve analysis, the potentially
most useful individual host markers, as determined by
area under the ROC curve (AUC >0.70) were IL-6 and
VEGF (Table 5).
When the concentrations of host markers detected
in saliva samples were compared between the active
TB group and ORD group, no significant differences
were observed for all the 10 markers investigated
(Table 6).
Differences in the expression of host biomarkers in
individuals with TB disease, LTBI and no Mtb infection
Of the 39 participants in the No TB group, 18 had a
negative QFT result. We compared the concentrations
of host markers detected in serum and saliva in individ-
uals with active PTB, LTBI or no Mtb infection, consid-
ering the QFT positive non-TB patients as LTBI. When
the concentrations of host markers detected in saliva
were compared between any two groups (PTB vs LTBI
or PTB vs No Mtb or LTBI vs No Mtb) none of the host
markers investigated (with the exception of IFN-γ
showed significant differences between the two groups
(Table 7, Fig. 3).
When the concentrations of host markers detected in
serum were compared between any two groups (PTB vs
Table 5 Median levels of the most promising host markers
detected in serum samples from patients with active TB group
(TB) or ORD group and accuracies in the diagnosis of TB disease
Groups TB Vs ORD
Marker IL-6 Serum VEGF Serum
ORD (median pg/ml) 6.9 (5.6–9.9) 57.06 (0–208.6)
PTB (Median pg/ml) 33.11 (12.9–60.2) 224.6 (93.2–654.9)
p-value <0.0001 0.001
AUC 0.85 0.71
Cut off >36.4 >573.8
Sensitivity 46.15 28.21
Specificity 97.44 97.44
Table 5: Shown are the median and ranges (in parenthesis) levels of serum
markers that were significantly different between the TB patients and the
group with other respiratory diseases (ORD) and area under the curve (AUC)
showing the diagnostic performance of the markers
Table 6 Median marker levels in saliva between the active PTB group and those with other respiratory infections and area under
the curve (AUC) showing diagnostic performance of markers
Marker Median (pg/ml) PTB Median (pg/ml) ORD p-value AUC Sensitivity Specificity Cut off
IL-2 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.57 0.53 89.74 15.38 <0.38
IL-5 1.6 (0.6–2.1) 1.6 (0.6–2.1) 0.52 0.54 12.82 97.44 <0.12
IL-6 5.11 (2.4–9.5) 4.8 (2.1–6.4) 0.23 0.58 25.64 89.74 <2.1
G-CSF 0.0 (0.0–40.5) 0.0 (0.0–53.2) 0.64 0.53 17.95 92.31 >86.61
GM-CSF 257.9 (77.9–428.9) 282.2 (36.3–405.5) 0.65 0.53 20.51 92.31 <6.53
MIP-1a 1.9 (1.1–2.6) 1.9 (1.3–2.3) 0.69 0.53 7.69 97.44 <0.55
MIP-1b 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.61 0.51 97.44 7.69 <31.06
VEGF 1486 (1004–1960) 1368 (550.5–2020) 0.24 0.58 28.21 92.31 <571.3
TNF-a 0.0 (0.0–8.5) 0.0 (0.0–4.3) 0.45 0.54 84.62 33.33 <5.32
IFNg 0.0 (0.0–15.6) 0.0 (0.0–7.7 0.18 0.57 71.79 41.03 <0.47
Table 4: Shown are the saliva marker levels (median levels and inter quartile ranges (in parenthesis) comparing active TB (PTB) participants with other respiratory
diseases (ORD) with Area Under the ROC curve ranging between 0.51–0.58
Table 7 Median markers levels in serum and saliva that were
significantly different between the active TB group (TB), latent
TB infection and uninfected (No TB infection) group
Groups PTB vs LTBI PTB vs HE LTBI vs HE
Marker IL-6 Serum VEGF Serum IFN-γ saliva
PTB Median
pg/ml
33.11
(12.9–60.3)
224.6
(93.2–654.9)
0
(0.0–15.6)
LTBI
(median pg/ml)
7.6 (5.6–10.7) 57.1 (0.0–230.3) 0 (0–16.7)
Uninfected
(median pg/ml)
6.7 (4.3–8.7) 69.8 (0.0–198.9) 0.0 (0.0–0.0)
p-value <0.0001 0.001 0.03 0.04
AUC 0.85 0.71 0.65 0.66
Cut off >36.4 >573.8 <0.47 <0.47
Sensitivity 46.15 28.21 88.9 88.9
Specificity 97.44 97.44 41 43
Table 6: Shown are the median levels of IL-6, VEGF IFN- γ and inter quartile
ranges (in parenthesis) for serum markers that were significantly different
between the active PTB, latent tuberculosis infection (LTBI) and the HE (No TB)
group. Area under the curve (AUC) showing the diagnostic performance
of markers
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LTBI or PTB vs No Mtb or LTBI vs No Mtb) the
concentrations of IL-6 and VEGF showed significant
difference between the two groups (Table 7). Except for
IFN-γ (p value 0.04) in saliva (Table 7, Fig. 4), serum
levels of IL-6 and VEGF were significantly different
between the active TB patients and latent TB infection
or uninfected (No TB individuals) with p-values ranging
between <0.0001 to 0.01 and area under the ROC curve
ranging between 071 and 0.86 (Table 7, Figs. 4, 5).
Utility of marker combinations for diagnosis of TB disease
When the general discriminant analysis technique was
used to assess the predictive abilities of combinations of
serum and salivary biomarkers for TB disease, a 5-marker
biosignature comprising of serum IL-6, MIP-1β, VEGF
and saliva G-CSF and MIP-1α, diagnosed TB disease in
the training sample set (n = 54; n = 27 TB cases and
n = 27 ORD), with a sensitivity of 81.5% (22/27) and
specificity of 100% (27/27), and with a sensitivity of 50%
(6/12) and specificity of 75% (9/12) in the test sample set
(n = 24, n = 12 TB cases and n = 12 ORD).
When only the saliva biomarkers were taken into
consideration, a 3-marker model comprising of salivary
G-CSF, TNF-α and VEGF diagnosed TB disease in the
training sample set (n = 54; n = 27 TB and n = 27 ORD)
with a sensitivity of 63% (17/27) and a specificity of 63%
(17/27). In the test sample set (n = 24; n = 12 TB,
n = 12 ORD) however, the sensitivity and specificity of
lo
g
le
v
e
ls
o
f
m
a
rk
e
rs
IL
-2
H
L T
Y
IL
-2
L T
B
I
IL
-2
P
T B
IF
N
-g
H
T L
Y
IF
N
-g
L T
B
I
IF
N
-g
P
T B
M
IP
-1
b
H
L T
Y
M
IP
-1
b
L T
B
I
M
IP
-1
b
P
T B
T N
F -
a
H
L T
Y
T N
F -
a
L T
B
I
T N
F -
a
P
T B
G
-C
S
F
H
T L
Y
G
-C
S
F
L T
B
I
G
-C
S
F
P
T B
IL
-5
H
T L
Y
IL
-5
L T
B
I
IL
-5
P
T B
M
IP
-1
a
H
T L
Y
M
IP
-1
a
L T
B
I
M
IP
-1
a
P
T B
IL
-6
H
T L
Y
IL
-6
L T
B
I
IL
-6
S
a l
iv
a
P
T B
G
M
-C
S
F
H
T L
Y
G
M
-C
S
F
L T
B
I
G
M
-C
S
F
P
T B
V
E
G
F
H
L T
Y
V
E
G
F
L T
B
I
V
E
G
F
P
T B
0
1 0
2 0
3 0
4 0
5 0
2 0 0 0
4 0 0 0
6 0 0 0
m a r k e r s in s a l iv a
M a r k e r s in s e r u m
lo
g
le
v
e
ls
o
f
m
a
rk
e
rs
IL
-2
H
L T
Y
IL
-2
L T
B
I
IL
-2
P
T B
G
M
-C
S
F
H
T L
Y
G
M
-C
S
F
L T
B
I
G
M
-C
S
F
P
T B
IL
-5
H
T L
Y
IL
-5
L T
B
I
IL
-5
P
T B
T N
F -
a
H
L T
Y
T N
F -
a
L T
B
I
T N
F -
a
P
T B
M
IP
-1
a
H
T L
Y
M
IP
-1
a
L T
B
I
M
IP
-1
a
P
T B
IL
-6
H
T L
Y
IL
-6
L T
B
I
IL
-6
P
T B
IF
N
-g
H
T L
Y
IF
N
-g
L T
B
I
IF
N
-g
P
T B
G
-C
S
F
H
T L
Y
G
-C
S
F
L T
B
I
G
-C
S
F
P
T B
V
E
G
F
H
L T
Y
V
E
G
F
L T
B
I
V
E
G
F
P
T B
M
IP
-1
b
H
L T
Y
M
IP
-1
b
L T
B
I
M
IP
-1
b
P
T B
0
2 0
4 0
6 0
8 0
1 0 0
2 0 0 0
4 0 0 0
6 0 0 0
P T B
N o T B (H e a lth y c o n tro ls )
L T B I
Fig. 3 Median and interquartile ranges of all 10 markers showing the differences between the active TB group (PTB), LTBI and the uninfected
(No TB) group in serum or saliva of all the study participants
Namuganga et al. BMC Infectious Diseases  (2017) 17:600 Page 7 of 11
the 3-marker salivary biomarker model were only 42%
(5/12) and 75% (9/12) respectively.
The most frequently occurring markers in the TB
disease predictive combinations comprised of serum
IL-6, VEGF, and MIP-1β as well as salivary G-CSF
and MIP-1α (Fig. 6).
Discussion
The search for biomarkers of TB disease and infection
requires the investigation and research on non-sputum
samples for TB diagnosis [17]. Early in biomarker re-
search, IFN-γ took the lead as a relevant TB biomarker.
It has however shown not to be a reliable biomarker if
not used in conjunction with other markers. With the
search for other biomarkers in TB research on the lead,
there’s a need for a non-sputum biological sample and
biomarker [18]. This study evaluated whether saliva
could serve as an alternative specimen to serum for TB
diagnosis. This owes to its non invasive nature of collec-
tion which can be applicable in children and the very ill
groups [19]. Recently, studies evaluating the relevance of
salivary host markers have shown promising markers
that could be incorporated in a point-of-care test follow-
ing validation [10, 11] and [13]. Overall, the levels of
markers were higher in serum for all participants except
for GM-CSF and VEGF. This confirms the findings by
Phalane et al. [13]. This study found increased levels of
VEGF and IL-6 in serum samples of active PTB patients
compared to those with other respiratory diseases. These
were also identified in previous studies [10, 11] and [13].
Increased VEGF in serum of patients with active TB
makes it a useful prognostic indicator in granulomatous
diseases, such as TB as identified by [20]. This suggests
its role in pathogenesis of pulmonary TB in the develop-
ment of the chronic inflammatory reaction.
In line with a study by Phalane et al. [13], increased
saliva levels of GM-CSF in this study are relevant to en-
hance T cell responses, regulate phagocytosis and innate
immune responses in alveolar macrophages [21]. High
GM-CSF levels have also been identified in saliva of
patients with oral squamous cell carcinoma [22].
Serum levels of MIP-1α, IL-6, TNF-α, IFN-γ and G-
CSF were noticeably higher than were in saliva. IL-6 and
TNF-α are pro-inflammatory cytokines which have a
role in granuloma formation [23]. MIP-1α and β are im-
portant chemo attractants for lymphocytes to the site of
TB infection leading to suppression of Mycobacterium
growth [24]. Findings by other investigators [25, 26] also
identified MIP-1α and β to be produced in high amounts
in TB disease. IFN-γ on the other hand is important in
promoting antigen presentation and recruiting T helper
and cytotoxic T cells involved in killing the bacilli. In
combination with TNF-α, they activate macrophages in
order to kill intracellular pathogens and induce produc-
tion of reactive nitrogen intermediates [27]. Serum levels
of markers are insufficient to base on for Mtb complex
diagnosis as we can’t pin their origin entirely to one
immune condition such as PTB [28]. For this reason,
salivary markers are being evaluated for their use in PTB
disease diagnosis.
When salivary marker levels were evaluated for their
ability to differentiate between active TB disease from
No TB disease, there was no significant difference
between the individual marker levels. Comparing with
serum, the concentrations of IL-6 and VEGF were
significantly different between the active TB disease
group and the ORD group. This may suggest that
salivary biomarkers may not be very useful individually
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in the diagnosis of TB disease. This may however, only
apply to the markers investigated in the current study as
previous reports identified salivary biomarkers which
showed potential in the diagnosis of TB disease (Phalane
et al., [13] Jacobs et al., [10] Jacobs et al. [11]). When
biomarkers were used in combinations however, a
biosignatures containing salivary biomarkers and combi-
nations between saliva and serum markers showed
potential. This correlates with findings by [29] and [30]
which reported high VEGF levels in active TB. Our
findings also suggest that Interleukin-6 as noted by pre-
vious studies by Jacobs et al., [10] and Phalane et al.,
[13] may be relevant for TB diagnosis. IL-6 appeared in
predictive combinations and is known to stimulate the
secretion of IFN-γ, a crucial cytokine in the activation of
macrophages infected with M.tb [31]. This correlates
with findings by [24] who identified increased serum
levels of IL-6 in active TB patients. IL-2 on the other
hand was below detectable levels for both serum and
saliva. It is a relevant T cell growth factor, macrophage
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activator [23] and contributes to T cell memory. Previ-
ous studies found IL-2 production to be reduced among
active PTB patients [32]. This may explain the low IL-2
levels shown given that all samples used were baseline
from TB suspects.
More investigations are required including studies
done on biomarkers other than the ones investigated in
the current study, given the potential that a diagnostic
tool based on saliva may contribute to the management
of TB disease in all patient types especially those with
difficulty in providing sputum samples such as children.
Such future studies should focus on the identification of
biosignatures, rather than individual biomarkers given
that these inflammatory biomarkers may not be highly
specific for TB, especially when used alone. Validated
salivary biosignatures could then be incorporated into
point-of-care tests for the diagnosis of TB disease
(Sutherland et al. [33]).
Conclusion
In conclusion, saliva may be an important alternative
diagnostic sample for PTB diagnosis and biomarker dis-
covery. Our findings suggest that biosignatures compris-
ing of combinations between different host markers
detected in saliva may be useful for the diagnosis of PTB
disease. We confirmed that there are highly significant
differences in the concentrations of some biomarkers
expressed in saliva in comparison to serum levels and
therefore biomarkers that do not show potential in
serum samples may not necessarily yield the same re-
sults in saliva. Therefore saliva warrants further explor-
ation as a sample for biomarker TB biomarker discovery
given that it is a very easily accessible sample and can be
collected from all patient types, and immunological as-
says based on saliva may be easily translated into simple,
culture-free point-of-care tests. Furthermore, saliva may
be a more informative sample type than serum as it is a
mucosal/airway linked sample and therefore is closer to
the site of disease than peripheral blood samples. Our
findings require further investigation in future larger
prospective studies.
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